These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 15050976

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [Abstract] [Full Text] [Related]

  • 43. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME.
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [Abstract] [Full Text] [Related]

  • 44. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S.
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [Abstract] [Full Text] [Related]

  • 45. Law and research could add up to profitable niche drugs.
    Haefner B.
    Nature; 2007 Apr 19; 446(7138):856. PubMed ID: 17443162
    [No Abstract] [Full Text] [Related]

  • 46. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG, Pawlik TM, Fader AN, Esnaola NF, Makary MA.
    Am J Clin Oncol; 2016 Apr 19; 39(2):210-3. PubMed ID: 26580246
    [Abstract] [Full Text] [Related]

  • 47. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM, Reed SD, Schulman KA.
    Health Aff (Millwood); 2012 Nov 19; 31(11):2528-35. PubMed ID: 23129684
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L, Lu CY, Agrawal PB, Asgari MM.
    J Am Acad Dermatol; 2019 Sep 19; 81(3):867-877. PubMed ID: 31103566
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. The Minor Use and Minor Species Animal Health Act: past, present, and future.
    Haley CJ.
    Food Drug Law J; 2006 Sep 19; 61(1):13-43. PubMed ID: 16838456
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V, Conte R, Landi A, Ottomano SA, Bonifazi D, Baiardi P, Bonifazi F, Ceci A.
    Orphanet J Rare Dis; 2017 Apr 03; 12(1):64. PubMed ID: 28372595
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Developing drugs for developing countries.
    Ridley DB, Grabowski HG, Moe JL.
    Health Aff (Millwood); 2006 Apr 03; 25(2):313-24. PubMed ID: 16522573
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN, Kartavtsova TV.
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014 Apr 03; (3):37-42. PubMed ID: 25219041
    [Abstract] [Full Text] [Related]

  • 60. Orphan drug regulations. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2013 Jun 12; 78(113):35117-35. PubMed ID: 23767079
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.